Abstract
AbstractTSPO ligands are promising alternatives to benzodiazepines in the treatment of anxiety, as they display less pronounced side effects such as sedation, cognitive impairment, tolerance development and abuse potential. In a randomized double-blind repeated-measures study we compare a benzodiazepine (alprazolam) to a TSPO ligand (etifoxine) by assessing side effects and acquiring resting-state fMRI data from 34 healthy participants after 5 days of taking alprazolam, etifoxine or a placebo. To study the effects of the pharmacological interventions in fMRI in detail and across different scales, we combine in our study complementary analysis strategies related to whole-brain functional network connectivity, local connectivity analysis expressed in regional homogeneity, fluctuations in low-frequency BOLD amplitudes and coherency of independent resting-state networks. Participants reported considerable adverse effects such as fatigue, sleepiness and concentration impairments, related to the administration of alprazolam compared to placebo. In resting-state fMRI we found a significant decrease in functional connection density, network efficiency and a decrease in the networks rich-club coefficient related to alprazolam. While observing a general decrease in regional homogeneity in high-level brain networks in the alprazolam condition, we simultaneously could detect an increase in regional homogeneity and resting-state network coherence in low-level sensory regions. Further we found a general increase in the low-frequency compartment of the BOLD signal. In the etifoxine condition, participants did not report any significant side effects compared to the placebo, and we did not observe any corresponding modulations in our fMRI metrics. Our results are consistent with the idea that sedation globally disconnects low-level functional networks, but simultaneously increases their within-connectivity. Further, our results point towards the potential of TSPO ligands in the treatment of anxiety and depression.
Funder
Deutsche Forschungsgemeinschaft
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Olsen RW. GABAA receptor: positive and negative allosteric modulators. Neuropharmacology. 2018;136:10–22.
2. Poisbeau P, Gazzo G, Calvel L. Anxiolytics targeting GABAA receptors: insights on etifoxine. World J Biol Psychiatry. 2018;19:S36–S45.
3. Rapoport M, Lanctot K, Bédard M, Vingilis E, Murray B, Schaffer A, et al. Benzodiazepine use and driving. J Clin Psychiatry. 2009;70:663–73.
4. Sadock J, Sadock A, Ruiz P. Kaplan and Sadock’s comprehensive textbook of psychiatry. In: Kaplan and Sadocks comprehensive textbook of psychiatry. Wolters Kluwer; 2017. https://books.google.de/books?id=gsDljwEACAAJ.
5. Edinoff A, Nix C, Hollier J, Sagrera C, Delacroix B, Abubakar T, et al. Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int. 2021;13:594–607.